TE-8035 is an ultralong-acting human insulin, in which 3 amino acids are site-specifically mutated and residue #29 lysine on B chain is conjugated with a fatty acid bundle with two C20 diacid long-chain fatty acid molecules.  TE-8035 has been compared with icodec, in which lysine at position B#29 is conjugated with a C20 diacid.

In a study comparing same single doses of TE-8035 and icodec in streptozocin-induced diabetic (STZ) mice, TE-8035 could lower blood glucose for longer periods than icodec.

In a study on STZ mice given 9 subcutaneous injections of TE-8035 or icodec in a q6d regimen, TE-8035 could lower HbA1c more effectively than icodec. We estimate that TE-8035 can be dosed in human patients once every week or 2 weeks (qw or q2w).

The molecular structure of TE-8035.

TE-8035 controlled blood glucose levels in STZ mice more effectively than icodec (a single dose for each). 


TE-8035 lowered blood glucose (as calculated by AUC) and reduced HbA1c over 54 days in a q6d regimen (9 subcutaneous administrations, made on day 0 and every 6 days until day 48) more effectively than icodec. (Unpaired tests, * p<0.05, ** p<0.01, **** p<0.0001)